drugset / Trial / NCT00391690

Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer

NCT00391690

Phase 4 Completed 99 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

It is the aim of this prospective, single-group, clinical study to assess whether bone parameters can be used as diagnostic tools for early detection of bone metastases in patients with high risk prostate cancer. The usefulness in monitoring zoledronic acid therapy in patients who have developed bone metastases will also be assessed.

Timeline

Start
2006-02
Primary completion
2010-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 4 mg

Indications